Granite Bio is a biotechnology business developing novel antibodies to treat inflammatory, autoimmune, and fibrotic disorders.
Granite Bio has raised $70.0M in total funding. The most recent round was Series B. The last funding was announced in April 2025.
Granite Bio's investors include Versant Ventures, Forbion Capital Partners, Novartis Venture Fund, Sanofi Ventures.
Granite Bio is headquartered in Basel, Switzerland.
Granite Bio is a biotechnology business developing novel antibodies to treat inflammatory, autoimmune, and fibrotic disorders.
Granite Bio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Granite Bio — Funding & Investors." VCBacked, April 24, 2025, https://www.vcbacked.co/company/granite-bio. Accessed October 28, 2026.
VCBacked. (2025). Granite Bio — Funding & Investors. Retrieved October 28, 2026, from https://www.vcbacked.co/company/granite-bio
{{cite web |title=Granite Bio — Funding & Investors |url=https://www.vcbacked.co/company/granite-bio |website=VCBacked |access-date=October 28, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated